Does MannKind Finally Have What It Takes To Get Afrezza Inhaled Insulin Cleared By FDA?
This article was originally published in The Pink Sheet Daily
Executive Summary
Among other things, new FDA review will test whether the company has proven that data with an old device can be applied to the new inhaler the company plans to market. MannKind is not expecting an advisory committee meeting.
You may also be interested in...
MannKind’s Long, Winding Development Road Ends In Approval Of Afrezza Inhaled Insulin
Firm now faces the commercial gauntlet of establishing an inhaled insulin in the crowded diabetes market.
Shutdown Week Two: Could Sponsors Find A More Focused FDA?
User-fee supported employees continue to work on pending reviews, and the lack of distractions from other tasks may help sponsors as the shutdown continues.
MannKind Gears Up To Make Commercial Case For Inhaled Insulin Afrezza
With two new positive Phase III studies, MannKind is getting back on regulatory track, with plans for a new FDA filing of Afrezza in the fourth quarter. Still, the firm is still planning more Phase IIIb/Phase IV studies to differentiate the inhaled insulin on the market.